Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy

Promise Of Safe And Effective Gene Editing Takes Step Forward

 
• By Andrew McConaghie
  
Intellia Therpeutics
Intellia's in vivo CRISPR therapies could rival other modalities, such as viral vector-based gene therapies and RNAi therapies. • Source: Intelllia
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip